Serina Therapeutics (SER) Preferred Stock Liabilities (2022 - 2023)
Serina Therapeutics' (SER) quarterly Preferred Stock Liabilities came in at $36.4 million in Q4 2023, up 36304.0% year-over-year from N/an in Q4 2022, and up 272.25% quarter-over-quarter from -$21.1 million in Q3 2023.
Powered by 
Analysis
Serina Therapeutics (SER) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Serina Therapeutics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $36.4 million for Q4 2023.
- In Q4 2023, Preferred Stock Liabilities rose 36304.0% year-over-year to $36.4 million; the TTM figure through Dec 2023 stood at $36.4 million (up 36304.0% YoY), while the FY2023 annual figure was $36.4 million, up 36304.0% from the prior year.
- Preferred Stock Liabilities came in at $36.4 million for Q4 2023 at Serina Therapeutics, up from -$21.1 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $36.4 million in Q4 2023 to a low of -$21.1 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Serina Therapeutics | 40.47 Mn | 17.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 36.40 Mn |
| Sep 30, 2023 | -21.14 Mn |
| Dec 31, 2022 | 100,000.00 |